Ad is loading...
SCCVX
Price
$14.54
Change
-$0.13 (-0.89%)
Updated
Nov 15 closing price
VISVX
Price
$49.63
Change
-$0.34 (-0.68%)
Updated
Nov 15 closing price
Ad is loading...

SCCVX vs VISVX

Header iconSCCVX vs VISVX Comparison
Open Charts SCCVX vs VISVXBanner chart's image
AB Small Cap Value C
Price$14.54
Change-$0.13 (-0.89%)
VolumeN/A
CapitalizationN/A
Vanguard Small Cap Value Index I
Price$49.63
Change-$0.34 (-0.68%)
VolumeN/A
CapitalizationN/A
SCCVX vs VISVX Comparison Chart
Loading...
View a ticker or compare two or three
VS
SCCVX vs. VISVX commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SCCVX is a Buy and VISVX is a Buy.

FUNDAMENTALS
Fundamentals
VISVX has more cash in the bank: 57.6B vs. SCCVX (621M). VISVX pays higher dividends than SCCVX: VISVX (1.90) vs SCCVX (0.00). SCCVX was incepted earlier than VISVX: SCCVX (10 years) vs VISVX (27 years). SCCVX is a more actively managed with annual turnover of: 59.00 vs. VISVX (16.00). SCCVX has a lower initial minimum investment than VISVX: SCCVX (2500) vs VISVX (3000). VISVX (28.71) and SCCVX (27.32) have marching annual gain over last year. VISVX return over 5 years is better than : 57.32 vs. SCCVX (22.49).
SCCVXVISVXSCCVX / VISVX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence10 years27 years-
Gain YTD12.80115.43383%
Front LoadN/AN/A-
Min. Initial Investment2500300083%
Min. Initial Investment IRAN/AN/A-
Net Assets621M57.6B1%
Annual Yield % from dividends0.001.90-
Returns for 1 year27.3228.7195%
Returns for 3 years-14.1713.23-107%
Returns for 5 years22.4957.3239%
Returns for 10 yearsN/A108.21-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DX12.420.04
+0.32%
Dynex Capital
PNR105.920.06
+0.06%
Pentair plc
TGNA17.64-0.47
-2.60%
TEGNA
HCTI1.16-0.04
-3.33%
Healthcare Triangle
ATOS1.28-0.09
-6.57%
Atossa Therapeutics